Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients

Advances in Therapy

Volumn 31, Issue 10, 2014, Pages 1082-1094

  Lin, Mao Fang ^a   Hou, Jian ^b   Chen, Wen Ming ^c   Huang, Xiao Jun ^d   Liu, Zhuo Gang ^e   Zhou, Yu Hong ^f   Li, Yan ^e   Zhao, Taiyun ^g   Wang, Lin Na ^g   Wu, Kwang Wei ^g   Shen, Zhi Xiang ^h  

^a ZHEJIANG UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^e CHINA MEDICAL UNIVERSITY   (China)

^f Department of Hematology of Zhejiang Province Traditional Chinese Medical Hospital ^*  (China)

^g Xian Janssen Pharmaceutical Ltd   (China)

^h SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bortezomib; Chinese; Multiple myeloma; Observational study; Refractory; Relapsed; Response

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN G; ANTINEOPLASTIC AGENT; PROTEASOME INHIBITOR;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER PATIENT; CANCER RECURRENCE; CHINESE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HERPES ZOSTER; HUMAN; HYPESTHESIA; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 4 CLINICAL TRIAL; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; CANCER STAGING; CHINA; DRUG MONITORING; DRUG RESISTANCE; ETHNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTINEOPLASTIC AGENTS; BORTEZOMIB; CHINA; DRUG MONITORING; DRUG RESISTANCE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROTEASOME INHIBITORS; RECURRENCE; TREATMENT OUTCOME;

EID: 84919871386     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0159-z     Document Type: Article

References (31)

1. Gupta M, Pal R, Tikoo D. Multiple myeloma: the disease and its treatment. Int J Basic Clin Pharmacol. 2013;2(2):103–21.
2. Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011;183:25–35.
3. Huang SY, Yao M, Tang JL, Lee WC, Tsay W, Cheng AL, et al. Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years. Cancer. 2007;110(4):896–905.
4. Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88(3):226–35.
5. Zeng Z, Lin J, Chen J. Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Ann Hematol. 2013;92(7):935–43.
6. Jakubowiak A. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives. Semin Hematol. 2012;49(Suppl 1):S16–32.
7. Fonseca R, Stewart AK. Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach. Mol Cancer Ther. 2007;6(3):802–10.
8. Blade J, Rosinol L. Changing paradigms in the treatment of multiple myeloma. Haematologica. 2009;94(2):163–6.
9. Larocca A, Palumbo A. Evolving paradigms in the treatment of newly diagnosed multiple myeloma. J Natl Compr Canc Netw. 2011;9(10):1186–96.
10. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165–72.
11. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–17.
12. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110:3557–60.
13. van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev. 2011;37(4):266–83.
14. Richardson P, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Chauhan D, et al. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007;2007(1):317–23.
15. Mohty B, El-Cheikh J, Yakoub-Agha I, Avet-Loiseau H, Moreau P, Mohty M. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents. Leukemia. 2012;26(1):73–85.
16. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006;91(11):1498–505.
17. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129(6):776–83.
18. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–17.
19. Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28(13):2259–66.
20. ®, (bortezomib), Prescribing Information. 2003. www.accessdata.fda.gov/drugsatfda_docs/label/…/021602s015lbl.pdf. Accessed July 14, 2014.
21. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8(6):508–13.
22. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2007;13(18):5291–4.
23. www.myeloma-euronet.org. Myeloma Euronet: Treatment with Bortezomib. 2013. http://www.myeloma-euronet.org/en/multiple-myeloma/treatment-with-bortezomibphp. Accessed July 14, 2014.
24. LoRusso PM, Venkatakrishnan K, Ramanathan RK, Sarantopoulos J, Mulkerin D, Shibata SI, et al. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res. 2012;18(10):2954–63.
25. Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, et al. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol. 2009;144(2):169–75.
26. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer. 2006;106(6):1316–9.
27. Lonial S, Richardson PG, San Miguel J, Sonneveld P, Schuster MW, Blade J, et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol. 2008;143(2):222–9.
28. Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin. 2007;57:301–18.
29. Bae J, Munshi NC, Anderson KC. Immunotherapy strategies in multiple myeloma. Hematol Oncol Clin North Am. 2014;28:927–43.
30. Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med. 2011;12:471–80.
31. Yuan ZG, Jin J, Huang XJ, Li Y, Chen WM, Liu ZG, et al. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China. Chin Med J (Engl). 2011;124(19):2969–74.